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Conclusion In acute exacerbation of COPD there is no difference
between 7-day and 14-day courses of treatment with oral predni-
solone. The peak of FEV1 and FVC in 7-day group on day-10 where
corticosteroid was already stopped on day-7, (peak in 14-day group
was on day-7) might be due to some other factor/factors responsible
which would be cleared by further study.
Clinical implications There was no difference between 7-day and 14-
day courses of prednisolone treatment, so, 7-day might be the
shortest effective course of steroid treatment in acute exacerbation
of COPD to avoid the burden of cost and side effects.
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Background Approximately 10% of patients with chronic obstruc-
tive pulmonary disease (COPD) have co-existing diabetes mellitus,
conferring an adverse prognosis. Metformin is a valuable first-line
treatment for diabetes. However, its rare association with lactic
acidosis limits its use among patients at risk of hypoxia. This may
deter some practitioners from prescribing it to patients with
significant co-existing COPD. It is unknown whether the benefits
of metformin outweigh its risks in this context. We therefore sought
to determine the effects of metformin on survival and length of stay
in a high-risk cohort of diabetic patients hospitalised for COPD
exacerbations.
Methods The medical records of diabetic patients hospitalised for
COPD were reviewed retrospectively. Length of hospital stay and
all-cause mortality were compared according to the presence or
absence of metformin therapy.
Results 130 patients were included, of whom 51 (39%) were
prescribed metformin. Patients on metformin had a shorter hospital
stay (median 7 vs 9 days respectively; p¼0.004). Survival at 90 days
was significantly better in the metformin group than in the non-
metformin group (94% vs 78% respectively; p¼0.015; Abstract P259
figure 1 inset). This persisted over the longer term, with overall
median (95% CI) survival of 5.2 years (4.3 to 6.1) in the metformin
group and 2.2 years (1.0 to 3.3) in the non-metformin group (HR
0.57; 95% CI 0.35 to 0.94; Abstract P259 figure 1). This difference
remained significant in a multivariate model, adjusting for potential
confounding effects of age, weight, acute illness severity (APACHE-
II score) and comorbidity burden. Among patients prescribed
metformin, vs those not, the median (IQR) plasma lactate concen-
tration was 1.45 mmol/l (1.10e2.05) vs 1.10 mmol/l (0.80e1.50),
respectively (p¼0.012).
Conclusion Diabetic patients hospitalised for COPD exacerbations
who were prescribed metformin were discharged earlier and survived
longer than those not prescribed metformin. Lactate concentration
was higher among patients on metformin, although the difference
was small. Our results suggest that the drug’s benefits may
outweigh its rare association with lactic acidosis. Whether this
reflects beneficial effects on diabetes- or COPD-related endpoints;
other associated conditions; or the effect of unmeasured
confounders, is unknown. We are now investigating this within the
context of a randomised controlled trial (ISRCTN66148745).
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Oral nutritional supplements (ONS) are often used to treat
malnutrition in COPD, but the latest Cochrane review in COPD
concluded that nutrition support, mainly involving ONS, did not
improve anthropometry and other functional outcomes.1 The latest
NICE guidelines for the management of COPD recommend the use
of ONS but state it is based on grade D evidence2 despite previous
reviews suggesting otherwise.3 This review aimed to clarify the
evidence base for ONS use in COPD. A systematic review identified
11 randomised controlled trials using ONS vs control (189 vs 185).
Meta-analysis was performed of nutritional intake, weight, mid-arm
muscle circumference (MAMC) and handgrip strength (HGS)
(Comprehensive Meta-analysis v2). Quality of life, exercise capacity
and respiratory outcomes were also examined. In contrast to
previous Cochrane reviews, examining only data at the end of
intervention,1 this review examined the changes induced by ONS.
Significantly improved energy intake was reported in six out of
seven studies of which four were meta-analysable (+262 SE
104 kcal/d, p¼0.012, random effect model, four RCT). Meta-anal-
ysis found ONS significantly improved body weight (+1.85 kg SE
0.25 kg, p<0.001 (malnourished) and +1.31 kg SE 0.34 kg, p<0.001
(nourished), 11 studies) and had a tendency to improve MAMC
(+0.21 kg SE 0.19 kg, p¼0.277, fixed effect model; I2¼0; 2 studies).
Improved HGS was found in three of four studies, two significant in
their own right with meta-analysis favouring ONS (+2.14 kg SE
1.1 kg, p¼0.054, random effect model (+8.3% improvement)). No
improvements were reported in FEV1 (eight studies) however,
respiratory muscle strength appeared more responsive to ONS with
PI max improved in three out of five studies (NS), PE max signifi-
cantly improved in two out of four studies and sternomastoid
strength significantly improved in one study. Exercise tolerance (six
out of seven studies), dyspnoea and general well-being (three out of
five studies) and quality of life (two out of two studies) were
significantly improved with ONS although meta-analysis of these
outcomes was not possible. ONS result in significant improvements
in nutritional intake and body weight and a tendency for
improvements in several functional outcomes. This would
support an increased level of evidence for ONS in the NICE COPD
guidelines.
Abstract P259 Figure 1 KaplaneMeier curves for all-cause mortality,
divided according to metformin use (p¼0.024, log-rank test). Inset:
survival curves at 90 days (p¼0.015, log-rank test).
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Introduction COPD accounts for one in eight hospital admissions, 1
million bed days and costs £870e930 m a year.1 Early treatment of
exacerbations with steroids reduces severity and may reduce the
need for hospital admission.2 We evaluated the acceptance and use
of a rescue pack provided on discharge from hospital.
Methods 38 patients, discharged between 1 February and 30 June
2011, were supplied a 7 day rescue pack comprising Prednisolone
25 mg and Doxycycline 100 mg (total cost of £7) with education
and a self-management plan.
A telephone questionnaire was conducted in July:
1. Do you remember being given a rescue pack on discharge
from hospital?
2. Have you had a flare-up of your COPD since discharge?
3. Did you use your rescue pack?
4. Did you take both antibiotic and steroid?
5. Did you complete the course?
6. Do you think it helped keep you at home?
7. Have you got a replacement rescue pack?
Results 25 out of 38 (66%) patients were contactable. 11 (44%) were
male and 14 (56%) female. The median age was 77 (range 53e89)
years. The median time from discharge to telephone contact was
110 (range 21e168) days. 24 (96%) patients acknowledged receipt of
the rescue pack. 14 out of 15 (93%) patients who had experienced an
exacerbation of COPD had used the rescue pack. Of these 14
patients, 13 (93%) were confident of the benefit and 10 (71%) had
obtained a replacement pack. Six of the 38 (16%) patients supplied
with a rescue pack were re-admitted with an exacerbation.
Conclusions The results of this service evaluation suggest a cost-
effective initiative that may reduce hospital re-admission by
promoting earlier treatment. Rescue packs should be supported by
education and a self-management plan.
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Introduction Breathlessness is the most common and frightening
symptom in Chronic Obstructive Pulmonary Disease (COPD).
Short-acting morphine (Oramorph) has traditionally been used to
treat breathlessness in palliative care. Although used in COPD
(Simon et al, 2010), there is no consensus/guidelines for prescribing
and patients stigmatise morphine, associating it with dying or
addiction. In this study, we assessed current prescribing practice,
patient use and safety of Oramorph, to inform local prescribing
guidelines and patient information.
Method Case notes of patients who were prescribed Oramorph for
breathlessness while having multidisciplinary COPD care between
2004 and 2011 were reviewed. The following were documented:
patient demographics, disease severity (FEV1, MRC dyspnoea score,
nebulisers, long term oxygen therapy (LTOT), domiciliary Non-
Invasive Ventilation (NIV), social/healthcare support and palliative
care referrals; Oramorph starting dosage, dosage range, increase in
dosage, patient choice to continue, duration of and use of morphine
sulphate slow release tablet (MST).
Results 28 COPD patients prescribed Oramorph for breathlessness
were identified (14 M), median (range) age 70 (52e83) years FEV1
(mean6SD) 0.5860.22, MRC dyspnoea score 4.660.49. 19/28 (68%)
were on LTOT, 28/28 (100%) on nebulisers, 5/28 (17%) on domiciliary
NIV, two current smokers, 10/28 (36%) lived alone, 27/28 (96%) had
professional healthcare domiciliary visits, 8/28 (29%) had palliative
care input. Starting, incremental and current dosing of Oramorph are
shown in theAbstract P262 table 1. 25/28 (89%) patients chose to stay
on Oramorph once started. Median (range) duration on Oramorph
was 8 months (45 dayse7.5 years).MSTwas added for breathlessness
in three patients. 13/28 (46%) patients died; all were MRC 5 and
starting Oramorph was not felt to be a contributing factor by the
clinical team. Time to death after starting Oramorph was median
(range) 7 months (68 dayse2.6 years). Oramorph prescribing in
COPD increased year-on-year (one patient in 2004 to 12 in 2010).
Conclusion Oramorph prescribed by a respiratory team for breath-
lessness is safe in this group of patients. This study indicates that its
effect is sustained despite low dosages with little requirement for
incremental dosing over time. Guidelines for prescribing and patient
information will be critical to ensure that patients are not denied
this useful treatment of breathlessness.
Abstract P262 Table 1
Oramorph Median dose mg Range dose mg
Starting dose (n¼28) 2.5 mg bd 1.25 mg bde5 mg qds
Increase (n¼12) 2.5 mg bd 2.5 mg bde10 mg qds
Current dose 2.5 mg bde2.5 mg qds 1.25 mg bde10 mg qds
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Background We are conducting a cross-sectional study of cannabis
and tobacco smokers in a primary care population and reporting
respiratory symptoms and lung function in two groups: Group
1¼persons who smoke tobacco cigarettes (branded cigarettes +/
“roll-your-own”); Group 2¼persons who smoke cannabis +/
tobacco cigarettes.
Methods Information on tobacco and cannabis smoking is obtained
from the Avon Longitudinal Study of Parents and Children. Cumu-
lative smoking is quantified by use of tobacco pack-years (py) and
joint years (jy). Additional tobacco use in cannabis smokers is
recorded. Other instruments used include the NHANES III andMRC
breathlessness questionnaires, measurement of ventilatory capacity
(Vitalograph a) and the Scottish Indices of Multiple Deprivation
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